Insider trading

Period: 12 months Stock: MPLT Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

35 decisions over 12 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

35 decisions over 12 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

35 decisions over 12 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

35 decisions over 12 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
35 decisions over 12 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
35 decisions over 12 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

35 decisions over 12 months
Stock
Insider
Type ?
Why it stands out
16 Sep 2026
Hanson Kristopher General Counsel
Sold on a plan
$192.66K 16,509 at 11.67
10.8%
Planned (10b5-1)
3 Aug 2026
Lillie James Woodruff Chief Scientific Officer
Sold on a plan
$276.91K 22,082 at 12.54
9.8%
Planned (10b5-1)
17 Jul 2026
Kreitzer Anatol Chief Discovery Officer
Sold on a plan 3×
$645.72K 17,173 at 37.60
8.9%
Planned (10b5-1)
17 Jul 2026
Foff Erin Pennock Chief Medical Officer
Sold on a plan
$138.56K 3,656 at 37.90
1.2%
Planned (10b5-1)
17 Jul 2026
Lillie James Woodruff Chief Scientific Officer
Sold at will
$78.72K 2,077 at 37.90
0.9%
Not planned
17 Jul 2026
Hanson Kristopher General Counsel
Sold at will
$42.83K 1,130 at 37.90
0.8%
Not planned
16 Jul 2026
Foff Erin Pennock Chief Medical Officer
Sold on a plan 3×
$553.33K 15,047 at 36.77
4.7%
Planned (10b5-1)
16 Jul 2026
Kreitzer Anatol Chief Discovery Officer
Sold on a plan 2×
$333.23K 9,056 at 36.80
4.5%
Planned (10b5-1)
16 Jul 2026
Lillie James Woodruff Chief Scientific Officer
Sold at will 3×
$314.41K 8,547 at 36.79
3.6%
Not planned
16 Jul 2026
Hanson Kristopher General Counsel
Sold at will 3×
$298.62K 8,118 at 36.78
5.2%
Not planned
15 Jul 2026
Foff Erin Pennock Chief Medical Officer
Sold on a plan 5×
$1.04M 28,455 at 36.64
8.2%
Planned (10b5-1)
15 Jul 2026
Kreitzer Anatol Chief Discovery Officer
Sold on a plan 2×
$366.94K 10,055 at 36.49
4.8%
Planned (10b5-1)
15 Jul 2026
Lillie James Woodruff Chief Scientific Officer
Sold at will 3×
$280.51K 7,643 at 36.70
3.1%
Not planned
15 Jul 2026
Hanson Kristopher General Counsel
Sold at will 3×
$266.43K 7,260 at 36.70
4.5%
Not planned
11 May 2026
Hanson Kristopher General Counsel
Sold on a plan 4×
$419.26K 13,917 at 30.13
7.9%
Planned (10b5-1)
7 May 2026
Foff Erin Pennock Chief Medical Officer
Sold on a plan 2×
$126.64K 4,438 at 28.54
1.3%
Planned (10b5-1)
7 May 2026
Lillie James Woodruff Chief Scientific Officer
Sold on a plan
$20.39K 721 at 28.28
0.3%
Planned (10b5-1)
6 May 2026
Lillie James Woodruff Chief Scientific Officer
Sold on a plan 2×
$713.60K 24,811 at 28.76
9.2%
Planned (10b5-1)
6 May 2026
Foff Erin Pennock Chief Medical Officer
Sold on a plan 2×
$691.75K 24,052 at 28.76
6.4%
Planned (10b5-1)
5 May 2026
Lillie James Woodruff Chief Scientific Officer
Sold on a plan 2×
$312.84K 11,095 at 28.20
4.0%
Planned (10b5-1)
5 May 2026
Foff Erin Pennock Chief Medical Officer
Sold on a plan 2×
$298.22K 10,576 at 28.20
2.7%
Planned (10b5-1)
4 May 2026
Lillie James Woodruff Chief Scientific Officer
Sold on a plan 4×
$441.81K 15,801 at 27.96
5.4%
Planned (10b5-1)
4 May 2026
Foff Erin Pennock Chief Medical Officer
Sold on a plan 4×
$437.63K 15,652 at 27.96
3.9%
Planned (10b5-1)
4 May 2026
Hanson Kristopher General Counsel
Sold on a plan 4×
$388.18K 13,917 at 27.89
7.3%
Planned (10b5-1)
28 Apr 2026
GILLIS JONATHAN CAAO and PAO
Sold on a plan 2×
$544.32K 17,935 at 30.35
9.0%
Planned (10b5-1)
27 Apr 2026
GILLIS JONATHAN CAAO and PAO
Sold on a plan 3×
$1.54M 51,900 at 29.74
20.7%
Planned (10b5-1)
27 Apr 2026
Kreitzer Anatol Chief Discovery Officer
Sold on a plan 3×
$1.35M 45,422 at 29.66
17.7%
Planned (10b5-1)
16 Apr 2026
Lillie James Woodruff Chief Scientific Officer
Sold at will 2×
$76.18K 2,783 at 27.37
0.9%
Not planned
16 Apr 2026
Foff Erin Pennock Chief Medical Officer
Sold at will 2×
$32.00K 1,169 at 27.37
0.3%
Not planned
16 Apr 2026
Hanson Kristopher General Counsel
Sold at will 2×
$8.16K 298 at 27.37
0.2%
Not planned
15 Apr 2026
GILLIS JONATHAN CAAO and PAO
Sold at will
$95.53K 3,590 at 26.61
1.4%
Not planned
15 Apr 2026
Kreitzer Anatol Chief Discovery Officer
Sold at will
$88.24K 3,316 at 26.61
1.3%
Not planned
15 Apr 2026
Foff Erin Pennock Chief Medical Officer
Sold at will
$54.86K 2,044 at 26.84
0.5%
Not planned
15 Apr 2026
Lillie James Woodruff Chief Scientific Officer
Sold at will
$46.40K 1,730 at 26.82
0.6%
Not planned
15 Apr 2026
Hanson Kristopher General Counsel
Sold at will
$40.98K 1,529 at 26.80
0.8%
Not planned
Showing 1–35 of 35.